SWOT Analysis for Windlas Biotech Ltd. - Weakness

Add SWOT widget to your site/app

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Consistent Highest Return Stocks over Five Years

Annual Profit Growth higher than Sector Profit Growth

Increasing Revenue every Quarter for the past 8 Quarters

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Companies with Low Debt

Increasing Revenue every Quarter for the past 4 Quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Top Gainers

Promoter decreasing their shareholding

PEG greater than Industry PEG

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

RSI indicating price weakness

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Stocks Underperforming their Industry Price Change in the Quarter

FII / FPI or Institutions increasing their shareholding

MFs decreased their shareholding last quarter

Rising Delivery Percentage Compared to Prev Day

Bullish or Bearish Candlestick Strength - Indices

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)